JP2001520042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001520042A5 JP2001520042A5 JP2000517087A JP2000517087A JP2001520042A5 JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5 JP 2000517087 A JP2000517087 A JP 2000517087A JP 2000517087 A JP2000517087 A JP 2000517087A JP 2001520042 A5 JP2001520042 A5 JP 2001520042A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- vitamin
- gla domain
- dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 44
- 150000001413 amino acids Chemical group 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 28
- 229930003448 Vitamin K Natural products 0.000 description 22
- 230000001419 dependent effect Effects 0.000 description 22
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 22
- 235000019168 vitamin K Nutrition 0.000 description 22
- 239000011712 vitamin K Substances 0.000 description 22
- 150000003721 vitamin K derivatives Chemical class 0.000 description 22
- 229940046010 vitamin k Drugs 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
| US08/955,636 | 1997-10-23 | ||
| PCT/US1998/022152 WO1999020767A1 (en) | 1997-10-23 | 1998-10-20 | Modified vitamin k-dependent polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001520042A JP2001520042A (ja) | 2001-10-30 |
| JP2001520042A5 true JP2001520042A5 (cg-RX-API-DMAC7.html) | 2006-01-05 |
| JP4276379B2 JP4276379B2 (ja) | 2009-06-10 |
Family
ID=25497114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000517087A Expired - Fee Related JP4276379B2 (ja) | 1997-10-23 | 1998-10-20 | 改変型ビタミンk依存性ポリペプチド |
Country Status (30)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| CA2391651A1 (en) * | 1999-11-19 | 2001-05-25 | Eli Lilly And Company | Protein c derivatives |
| AU2001232736A1 (en) | 2000-02-02 | 2001-08-14 | Eli Lilly And Company | Protein c derivatives |
| WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| WO2001059084A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| AU2001278336B2 (en) * | 2000-07-31 | 2007-01-18 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| AU2002235073B2 (en) * | 2001-03-02 | 2007-02-01 | T.A.C. Thrombosis And Coagulation Ab | Protein C variants |
| WO2003073980A2 (en) * | 2002-03-01 | 2003-09-12 | T.A.C. Thrombosis And Coagulation Aktiebolag | Recombinant protein c variants |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| DE60334983D1 (de) * | 2002-04-30 | 2010-12-30 | Bayer Healthcare Llc | Faktor vii oder faktor viia polypeptidvarianten |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| CN101912601B (zh) | 2002-06-21 | 2012-08-29 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| EP3103869A1 (en) | 2003-03-18 | 2016-12-14 | Novo Nordisk Health Care AG | Method for the production of factor vii polypeptides |
| EP2085470B1 (en) * | 2003-03-20 | 2012-05-16 | Bayer HealthCare LLC | FVII or FVIIa variants |
| JP4915918B2 (ja) * | 2003-06-19 | 2012-04-11 | バイエル ヘルスケア エルエルシー | 第VII因子または第VIIa因子のGlaドメイン変種 |
| CN101870729A (zh) | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| AU2004294403A1 (en) | 2003-12-01 | 2005-06-16 | Novo Nordisk Health Care Ag | Nanofiltration of factor VII solutions to remove virus |
| EP2311437A1 (en) | 2003-12-19 | 2011-04-20 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| EP1831242B1 (en) | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| JP5147692B2 (ja) | 2005-07-13 | 2013-02-20 | ノボ ノルディスク ヘルス ケア アーゲー | 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞 |
| CN101268185B (zh) | 2005-09-01 | 2013-03-27 | 诺沃-诺迪斯克保健股份有限公司 | 因子ⅶ多肽的疏水作用色谱纯化 |
| JP5690047B2 (ja) | 2005-09-14 | 2015-03-25 | ノボ ノルディスク ヘルス ケア アーゲー | ヒト凝固第vii因子ポリペプチド |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| WO2008078189A2 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| RU2571931C2 (ru) | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| SI2574677T1 (sl) | 2007-12-27 | 2017-11-30 | Baxalta GmbH | Procesi celične kulture |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
| DK3266463T3 (da) | 2009-06-09 | 2024-01-08 | Prolong Pharmaceuticals Llc | Hæmoglobinsammensætninger |
| CN102686603B (zh) * | 2009-12-14 | 2014-12-17 | 国立大学法人北海道大学 | 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体 |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| KR102049900B1 (ko) | 2012-07-25 | 2019-11-28 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 인자 x 폴리펩티드 및 이의 용도 |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| EP3833381B1 (en) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296413A2 (en) * | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインc及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Ceased
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Ceased
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| Sadler | Thrombomodulin structure and function | |
| Kato et al. | Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme | |
| TW585871B (en) | Improved methods for processing activated protein C | |
| Clark et al. | Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phosoholipase C in mammalian cells | |
| WO2001045746A3 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
| CA2400295A1 (en) | Modified factor viii | |
| US6465624B1 (en) | Purification of von-Willebrand factor by cation exchanger chromatography | |
| US8022187B2 (en) | FVIII-independent FIX-mutant proteins for hemophilia A treatment | |
| CA2102208A1 (en) | Binding domains in notch and delta proteins | |
| JP2002513556A5 (cg-RX-API-DMAC7.html) | ||
| KR20160008521A (ko) | 콜레스테롤 수준을 변경하는 조성물 및 방법 | |
| AU2008209985A1 (en) | Improved fix-mutant proteins for hemophilia B treatment | |
| KR910003094A (ko) | 흡혈박쥐속(Vampire bat) 타액 플라스미노겐 활성인자 | |
| CA2563675A1 (en) | Recombinantly modified plasmin | |
| Orawski et al. | Purification and properties of membrane-bound aminopeptidase P from rat lung | |
| AU2444795A (en) | A process for separating milk clotting enzymes, and stable rennet compositions | |
| Friedman et al. | Vitamin K-dependent carboxylation | |
| JP7843331B2 (ja) | 第xa因子及び誘導体を調製するための組成物及び方法 | |
| CA1258242A (en) | Urokinase zymogen and composition containing the same | |
| Noda et al. | Activation of immobilized, biotinylated choleragen A1 protein by a 19-kilodalton guanine nucleotide-binding protein | |
| Vatandoost et al. | Effect of propeptide amino acid substitution in γ‐carboxylation, activity and expression of recombinant human coagulation factor IX | |
| ATE121456T1 (de) | Klonierung und überexpression von glucose-6- phosphat-dehydrogenase aus leuconostoc dextranicus. | |
| JPH05506354A (ja) | 端が切り取られた軽鎖を有する活性プロテインc | |
| Fischer et al. | Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells |